1 |
Di Bartolo B, Scherer DJ, Brown A, Psaltis PJ, Nicholls SJ. PCSK9 inhibitors in hyperlipidemia: current status and clinical outlook. BioDrugs 2017;31:167-74.
DOI
|
2 |
Haas ME, Levenson AE, Sun X, Liao WH, Rutkowski JM, de Ferranti SD, et al. The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation 2016;134:61-72.
DOI
|
3 |
Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003;42:1121-30.
DOI
|
4 |
Muso E. Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin Exp Nephrol 2014;18:286-90.
DOI
|
5 |
Sato T, Liang K, Vaziri ND. Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int 2002;61:157-62.
DOI
|
6 |
Gentile MG, Fellin G, Cofano F, Delle Fave A, Manna G, Ciceri R, et al. Treatment of proteinuric patients with a vegetarian soy diet and fish oil. Clin Nephrol 1993;40:315-20.
|
7 |
Hall AV, Parbtani A, Clark WF, Spanner E, Huff MW, Philbrick DJ, et al. Omega-3 fatty acid supplementation in primary nephrotic syndrome: effects on plasma lipids and coagulopathy. J Am Soc Nephrol 1992;3:1321-9.
DOI
|
8 |
Bell S, Cooney J, Packard CJ, Caslake MJ, Deighan CJ. The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria. Clin Nephrol 2012;77:445-53.
DOI
|
9 |
Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 1988;2:1335-8.
|
10 |
Thomas ME, Harris KP, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993;44:1124-9.
DOI
|
11 |
Brown CD, Azrolan N, Thomas L, Roberts KG, Bostom A, Zhao ZH, et al. Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome. Am J Kidney Dis 1995;26:170-7.
DOI
|
12 |
Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994;23:331-46.
DOI
|
13 |
Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995;48:188-98.
DOI
|
14 |
Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L, et al. Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev 2013;(12):CD005425.
|
15 |
Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993;44:638-42.
DOI
|
16 |
Mehta A, Mishra S, Ahmad K, Tiwari HC, Singh V, Singh A. Carotid intima media thickness in children with nephrotic syndrome: an observational case control study. Sudan J Paediatr 2019;19:110-6.
|
17 |
Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 1993;22:135-42.
DOI
|
18 |
Gyebi L, Soltani Z, Reisin E. Lipid nephrotoxicity: new concept for an old disease. Curr Hypertens Rep 2012;14:177-81.
DOI
|
19 |
Chung JJ, Huber TB, Godel M, Jarad G, Hartleben B, Kwoh C, et al. Albumin-associated free fatty acids induce macropinocytosis in podocytes. J Clin Invest 2015;125:2307-16.
DOI
|
20 |
Allison SJ. Podocyte biology: free fatty acid-induced macropinocytosis in podocytes. Nat Rev Nephrol 2015;11:386.
DOI
|
21 |
D'Amico G, Gentile MG, Manna G, Fellin G, Ciceri R, Cofano F, et al. Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome. Lancet 1992;339:1131-4.
DOI
|
22 |
Eddy AA, Michael AF. Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. Kidney Int 1988;33:14-23.
DOI
|
23 |
Eddy AA, McCulloch L, Liu E, Adams J. A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am J Pathol 1991;138:1111-23.
|
24 |
Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 2005;(99):S87-93.
|
25 |
Liu S, Vaziri ND. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol Dial Transplant 2014;29:538-43.
DOI
|
26 |
Morris AW. Nephrotic syndrome: PCSK9: a target for hypercholesterolaemia in nephrotic syndrome. Nat Rev Nephrol 2016;12:510.
DOI
|
27 |
Jin K, Park BS, Kim YW, Vaziri ND. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis 2014;63:584-9.
DOI
|
28 |
Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982;2:1309-11.
|
29 |
Clement LC, Mace C, Avila-Casado C, Joles JA, Kersten S, Chugh SS. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 2014;20:37-46.
DOI
|
30 |
Vaziri ND, Liang K. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 2002;61:1769-75.
DOI
|
31 |
Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 2020;4:CD002290.
|
32 |
Vaziri ND, Liang KH. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.Circulation 2004;110:419-25.
DOI
|
33 |
Vaziri ND, Liang KH. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995;48:1979-85.
DOI
|
34 |
Vaziri ND, Sato T, Liang K. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 2003;63:1756-63.
DOI
|
35 |
Kang HG, Cheong HI. Nephrotic syndrome: what's new, what's hot? Korean J Pediatr 2015;58:275-82.
DOI
|
36 |
Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018;14:57-70.
|
37 |
Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int 2016;90:41-52.
DOI
|
38 |
Vaziri ND, Yuan J, Ni Z, Nicholas SB, Norris KC. Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin Exp Nephrol 2012;16:238-43.
DOI
|
39 |
Coleman JE, Watson AR. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 1996;10:171-4.
DOI
|
40 |
Khurana M, Silverstein DM. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. Pediatr Nephrol 2015;30:2073-84.
DOI
|
41 |
Sanjad SA, al-Abbad A, al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr 1997;130:470-4.
DOI
|
42 |
Groggel GC, Cheung AK, Ellis-Benigni K, Wilson DE. Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney Int 1989;36:266-71.
DOI
|
43 |
Buyukcelik M, Anarat A, Bayazit AK, Noyan A, Ozel A, Anarat R, et al. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. Turk J Pediatr 2002;44:40-4.
|
44 |
Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol 2009;5:507-18.
DOI
|
45 |
Valeri A, Gelfand J, Blum C, Appel GB. Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. Am J Kidney Dis 1986;8:388-96.
DOI
|
46 |
Raina R, Krishnappa V. An update on LDL apheresis for nephrotic syndrome. Pediatr Nephrol 2019;34:1655-69.
DOI
|
47 |
Jatem E, Lima J, Montoro B, Torres-Bondia F, Segarra A. Efficacy and safety of PCSK9 inhibitors in hypercholesterolemia associated with refractory nephrotic syndrome. Kidney Int Rep 2020;6:101-9.
|